UOB Kay Hian Research Articles

IHH Healthcare - 2Q22 Blip as Admissions See An Unequal Recovery

Publish date: Fri, 26 Aug 2022, 12:15 PM
0 1,987
An official blog in I3investor to publish research reports provided by UOB Kay Hian research team.

All materials published here are prepared by UOB Kay Hian. For latest offers on UOB Kay Hian trading products and news, please refer to: http://www.utrade.com.my

UOB Kay Hian Securities (M) Sdn Bhd (194990-K)

1800 UTRADE /
1800 88 7233 (Securities)
+6088 235611 (Futures)

Email: contact@utrade.com.my
  • IHH Healthcare saw an uneven recovery in patient volume admission as COVID-19-related contributions moderated as expected.
  • Acibadem’s solid domestic performance was dented by its hyper-inflationary environment as earnings were curtailed. This confluence of factors dragged on earnings, below our expectations. However, eventual admission recovery should support its earnings going forward.
  • Maintain BUY with a target price of RM7.10.

IHH Healthcare's 2Q22 Below Our Estimate But Within Consensus Expectations

  • IHH Healthcare’s 2Q22 core profit of RM318m contracted 22.1% y-o-y (-31.5% q-o-q). It brought 1H22 core profit to RM725m (-9.3% y-o-y). It is below our estimate but within consensus full-year estimates at 42% and 45% of full-year earnings respectively.
  • The negative variance is hyper-inflationary conditions weighing more than expected on Acibadem’s contributions and shortfall in inpatient admission recovery to offset moderating COVID-19-related contributions.

Malaysia Almost Back to Pre-pandemic Levels as Moderating COVID-19 Contributions Weigh on Singapore

  • Singapore operations’ top-line was flattish at 0.8% y-o-y. This was amid flattish inpatient admission (-0.7% y-o-y) but higher revenue intensity (+21.9% y-o-y) attributed to better case mix with a higher proportion of acute patients seeking treatment. Inpatient admission remains 20% below pre-pandemic levels. The tapering of COVID-19- related revenue to 5% of revenue (1Q22: 22%) was a contributing factor to flattish revenue. EBITDA earnings contracted 6.0% y-o-y off lower margins.
  • In contrast, Malaysia continues to realise a swift recovery in inpatient admission (+31.2% y-o-y). The higher elective case mix diluted revenue intensity (-7.1% y-o-y) as COVID-19 contributions moderated to 3% revenue (from 8% in 1Q22). EBITDA earnings grew 20% y-o-y off enhanced margins from the positive operating leverage.

Solid Domestic Performance But Hyper-inflation Translation Weighs on Acibadem’s Contributions

  • Meanwhile, Acibadem’s revenue was flattish (+0.2% y-o-y) as patient volume (+11%) and revenue intensity in ringgit terms (+16% y-o-y, in local currency terms: +46%) grew. However due to the hyper-inflationary environment, earnings in ringgit terms contracted by 35%. Acibadem’s operations contributed between 25-30% of EBITDA earnings previously.
  • Meanwhile in India, absence of COVID-19-related contributions weighed on revenue (-2.0% y-o-y) despite registering positive inpatient volume (21.7% y-o-y).

IHH Healthcare - Earnings Forecast Revision and Recommendation

  • We cut our 2022-24 earnings forecasts for IHH Healthcare by 12/7/10% to account for lower patient volume admission and Acibadem contributions.
  • Maintain BUY recommendation on IHH Healthcare with a lower SOTP-based target price of RM7.10 (from RM7.30). SOTP-based equity value of RM61,884mil consists of
    • Parkway Pantai Limited (100% equity stake): RM39,846mil.
    • Acibadem (90% equity stake): RM11,259mil.
    • Fortis (31.1% equity stake): RM6,424mil.
    • IMU Health (100% equity stake): RM1,509mil.
    • Parkway Life REIT (SGX:C2PU) (35.7% equity stake): RM2,846mil.
  • Our SOTP-based target price implies 37.4x 2022F P/E, or close to its -1 standard deviation of its 5-year mean P/E.
  • Valuations appear attractive with:
    • resilient yet defensive 3-year earnings (2021-24F) CAGR of 4.2%, and
    • IHH Healthcare’s sound track record. The attractive valuation outweigh the hyper-inflationary risks associated with Acibadem.
  • Key downside risks are:
    • execution risk,
    • shortfall in turning around Fortis, and
    • heightened regulatory hurdles.

Source: UOB Kay Hian Research - 26 Aug 2022

Related Stocks